SYBX — Synlogic, Inc.

Summary of Synlogic's Q2 2022 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $0.2 million for Q2 2022, consistent with Q2 2021, primarily from a collaboration with Roche.
• Net Loss: $15.7 million for Q2 2022, slightly higher than the $15 million loss in Q2 2021.
• Cash Position: Ended Q2 2022 with $106.8 million in cash and equivalents, down from $120.5 million at the end of Q1 2022. The company expects this cash to fund operations into 2024.

2. Strategic Updates and Business Highlights

• Clinical Programs:
  • Received a positive opinion for orphan drug designation from the EMA for SYNB 1618, targeting phenylketonuria (PKU).
  • Anticipates three clinical data readouts in 2022: Phase II data for PKU, Phase I data for SYNB 1353 (for homocystinuria), and proof of concept data for SYNB 8802 (for enteric hyperoxaluria).
  • Introduced SYNB 2081 for gout, developed in partnership with Ginkgo Bioworks, aimed at addressing unmet needs in gout treatment.
• Regulatory Progress: Preparing for a Phase III study for PKU in early 2023, with trial readiness activities underway.

3. Forward Guidance and Outlook

• Upcoming Milestones:
  • Expecting Phase II data readouts and confirmation of Phase III candidates later in 2022.
  • Plans to initiate Phase III study for PKU in the first half of 2023.
• Market Positioning: Focused on severe PKU patients and those who are treatment-resistant, indicating strong market interest in new therapies.

4. Challenges and Points of Concern

• Enrollment Challenges: Potential difficulties in enrolling patients for the Symphony trial due to ongoing recovery from the pandemic, as noted by other companies in the PKU space.
• Market Dynamics: Observations of slower recovery rates in treatment centers could impact expectations for market opportunity, although management remains optimistic about interest in new therapies.
• Manufacturing and Regulatory Risks: While there is positive engagement with the FDA regarding CMC requirements, final agreements are pending, which could pose risks to timelines.

5. Notable Q&A Insights

• Enrollment Expectations: Management anticipates faster enrollment for Phase III compared to Phase II due to more sites and a less intensive study design.
• Age and Efficacy: There are considerations for including pediatric patients in future studies, with an understanding that endpoints may need to be adjusted based on age-related differences in PKU management.
• Gout Program: The potential impact of SYNB 2081 on endogenous uric acid production was discussed, with indications that the treatment could affect both dietary and systemic sources of uric acid.

Overall, Synlogic is navigating a promising yet challenging landscape as it advances its clinical programs while managing financial and operational hurdles.